Opens in a new tab

High-Quality Glass Manufacturing

High-Quality Glass Manufacturing
Country
KazakhstanKazakhstan
Listing ID
L#20250923
Target Price
$3,211,734
Revenue
TBD
EBITDA
TBA

Description

An operational glass product manufacturing facility located in Astana, Republic of Kazakhstan. The business features well-established production and sales operations, with a prime urban location offering excellent transport connectivity.

Keypoints

  • Land area: 1.5 hectares (leased)

  • Production facility: 2,000 sq. meters

  • Office space: 1,000 sq. meters

  • On-site railway siding with crane for freight handling

  • Electrical substation with a capacity of 1.6 MW

  • Fully equipped with all necessary production machinery:

  • CNC machines, plotters, welding machines

  • Ovens, compressors, and auxiliary equipment

  • Includes vehicles, loading equipment, and heavy-duty machinery

Basic Details

Listing ID
L#20250923
Country
Kazakhstan
City
Astana
Industry
Manufacturing
Deal Status
Available
Target Price
$3,211,734
Revenue
TBD
EBITDA
TBA
Revenue Multiple
TBD
EBITDA Multiple
TBD

M&A Middle Market Advisory Deal Tombstones 2024

AdvisorDeals
MergersCorp M&A International21
Keith Advisory17
GCG9
JP Morgan41
Jefferies23
Lazard26
Goldman Sachs30

Businesses for Sale

Similar Opportunities

KazakhstanKazakhstanManufacturingL#20261174

Central Asian Chlor-Alkali & Chemicals Manufacturing Platform

The proposed project entails the development of a state-of-the-art, vertically integrated chlor-alkali and downstream specialty chemical manufacturing cluster in Kazakhstan. Capitalizing on abundant domestic salt reserves, competitive operating fundamentals, and strategic Eurasian logistics corridors, the project is structured to substitute…

Target Price
$1,000,000,000
Revenue
$620,000,000
EBITDA
$186,000,000
United StatesUnited StatesManufacturingL#20261103

American Leading Life Sciences Research Services Platform

A leading independent multi-omics service providers in the Americas. The Company provides a comprehensive portfolio of next-generation sequencing (NGS), proteomics, metabolomics, epigenomics, and bioinformatics solutions to research institutions, hospitals, biotechnology companies, and pharmaceutical clients across North and South America. Following…

Target Price
$44,000,000
Revenue
$57,000,000
EBITDA
$3,700,000